Metropolis Healthcare Q2 FY26 Performance Analysis

Metropolis Healthcare Ltd. has reported a robust financial and operational performance for the second quarter of the fiscal year 2025-26, ending September 30, 2025. The results indicate significant top-line and bottom-line growth, driven by strong volumes and the successful execution of strategic initiatives. Key Financial Highlights (YoY) Net Profit: Grew 13.2% year-on-year to ₹53 crore, compared to ₹47 crore in the prior-year period. Revenue from Operations: Increased 22.7% YoY to ₹429 crore, up from ₹349.8 crore. EBITDA: Rose 20.5% YoY to ₹108.6 crore. EBITDA Margin: Stood at 25.3%, reflecting a minor compression from 25.7% in Q2FY25, but demonstrating strong cost management amidst expansion. Operational & Strategic Drivers Volume & Segment Growth: The company achieved robust 11% growth in patient volume and 12% growth in test volume. This was broad-based, with B2C revenue climbing 16% and B2B revenue expanding significantly by 33% YoY. Premiumization & Efficiency: Revenue per Patient (RPP) and Revenue per Test (RPT) improved by 11% and 10% YoY, respectively. This highlights successful premiumization and portfolio mix enhancement. High-Value Portfolio: Strategic focus areas performed exceptionally well. The TruHealth wellness portfolio recorded ~24% YoY growth, while the Specialty portfolio grew ~33% YoY. M&A & Integration Success: The company's integration strategy is validated by the swift turnaround of Core Diagnostics, which achieved positive PAT within two quarters of acquisition. Subsidiaries DAPIC and Scientific Pathology continue to outperform company average margins. Geographic Expansion: The North India revenue contribution increased to 19% (from 17% in Q1FY26), indicating successful market penetration. Shareholder Value In recognition of the strong performance, the Board has declared an interim dividend of ₹4 per equity share (Face Value ₹2) for FY26. The record date for this dividend is set for November 11, 2025.